{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-009695","form_type":"8-K","ticker":"OPK","cik":"0000944809","company_name":"OPKO HEALTH, INC.","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.378649+00:00","generated_at":"2026-06-04T06:53:37.103467+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"OPKO Health sells BioReference clinical diagnostics business to LabCorp for ~$237.5M","bullets":["Asset Purchase Agreement with LabCorp for $237.5M cash, excluding oncology/urology and NY/NJ operations.","Transaction includes transfer of certain BioReference employees; no financing condition required.","Closing subject to HSR clearance and customary conditions; 180-day outside date with potential extensions.","Termination fee payable by LabCorp in certain circumstances if regulatory clearance fails.","OPKO retains nationwide oncology/urology and all NY/NJ operations post-closing."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-009695","json":"https://secwatch.observer/filing/0001437749-24-009695.json","markdown":"https://secwatch.observer/filing/0001437749-24-009695.md","text":"https://secwatch.observer/filing/0001437749-24-009695.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/944809/000143774924009695/0001437749-24-009695-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/944809/000143774924009695/opk20240311_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T06:53:37.103467+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"abfa0f8ea31b7d71b82931f5a12d8ff604f412c3","claim":"OPKO HEALTH, INC. entered into Asset Purchase Agreement with Laboratory Corporation of America Holdings valued at approximately $237,500,000 in cash (effective 2024-03-27).","evidence_excerpt":"On March 27, 2024, OPKO Health, Inc., a Delaware corporation (“ OPKO ”), its wholly owned subsidiary, BioReference Health, LLC (“ BioReference ” and together with OPKO, “ Seller ”), and Laboratory Corporation of America Holdings, a Delaware corporation (“ Buyer ”), entered into an Asset Purchase Agreement (the “ Purchase Agreement ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/944809/000143774924009695/0001437749-24-009695-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Laboratory Corporation of America Holdings"},{"label":"Value","value":"approximately $237,500,000 in cash"},{"label":"Effective","value":"2024-03-27"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}